San Diego-based VentiRx Pharmaceuticals announced today that it has raised $28.9M in funding for the firm's treatments for cancer and infection, respiratory, and autoimmune diseases. The funding came from Frazier Healthcare Ventures, ARCH Venture Partners and Domain Associates. $26.6M of the investment came in the firm's Series A, the other $2.3M was part of a seed funding. More information »